FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
	hurdon								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

37 Estimated average burden hours per response: 0.5

					or S	Section	30(h)	of the	Investme	ent Co	mpany Act	of 1940)							
l	1. Name and Address of Reporting Person* STAAB THOMAS R II				BI	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX]									Check	all app	plicable)		Person(s) to Issuer 10% Owner Other (specify	
(Last) 4505 EM SUITE 20	505 EMPEROR BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 12/21/2015										X Office (give title Office (specify below) Senior Vice President and CFO					
(Street) DURHA			27703 Zip)		_ 4. If	Line) X Form filed by C								n filed by One n filed by Mor	up Filing (Check Applicable ne Reporting Person ore than One Reporting					
		Tabl	e I - No	on-Deriv	ative	Sec	uritie	s Ac	quired	l, Dis	sposed o	f, or	Ber	neficia	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)					Execut y/Year) if any		Deemed cution Date, y nth/Day/Year)				es Acquired (A) o Of (D) (Instr. 3, 4 a			and 5) Se Be Ov		ecurities eneficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)		Price	Transaction(s) (Instr. 3 and 4)		action(s)			(msu. 4)
Common Stock 12/21/				2015				s 3,052		I		\$10.86(1)		136,592			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	on Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		nstr. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	nership rm: ect (D) Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Nu of	ımber						

Explanation of Responses:

1. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$10.85 to \$10.87. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

> /s/ Alane P. Barnes, by power of attorney

12/22/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.